EUVIMEDEUVIMED entdecken
Crossref

In Brief: An Expanded Indication for Teplizumab (Tzield)

The Medical Letter on Drugs and Therapeutics · 22.06.2026 · 68 (1757) · 100-101

DOI: 10.58347/tml.2026.1757c ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 22.06.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CD3-directed monoclonal antibody teplizumab (Tzield – Provention Bio), which was previously approved by the FDA to delay the onset of stage 3 type 1 diabetes in patients ≥8 years old with stage 2 type 1 diabetes, has now been approved for such use in children 1-7 years old.

Schlagwörter

Stichwörter der Autor:innen

Tzieldadverse effectsdosageefficacysafetyteplizumabtype 1 diabetes

Zitieren

APA

(2026). In Brief: An Expanded Indication for Teplizumab (Tzield). The Medical Letter on Drugs and Therapeutics, 68(1757), 100-101. https://doi.org/10.58347/tml.2026.1757c

Vancouver

In Brief: An Expanded Indication for Teplizumab (Tzield). The Medical Letter on Drugs and Therapeutics. 2026;68(1757):100-101. doi:10.58347/tml.2026.1757c

BibTeX
@article{euvimed2026,
  title = {In Brief: An Expanded Indication for Teplizumab (Tzield)},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1757},
  pages = {100--101},
  doi = {10.58347/tml.2026.1757c}
}
Kostenlos starten →